stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Return on equity
Arcus Biosciences, Inc.'s return on equity over the twelve months to 30 September 2026 was −114.1%, down 50.8 percentage points from fiscal 2025 (−63.3%). Over the past ten years it has ranged from −63.3% (fiscal 2025) to 115.0% (fiscal 2017) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −63.3% | (3.49) |
| FY2024 | −59.8% | (4.90) |
| FY2023 | −54.9% | (19.25) |
| FY2022 | −35.6% | (43.51) |
| FY2021 | 7.89% | 44.82 |
| FY2020 | −36.9% | 5.55 |
| FY2019 | −42.5% | 18.52 |
| FY2018 | −61.0% | (175.99) |
| FY2017 | 115.0% | 75.92 |
| FY2016 | 39.1% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BEAM Beam Therapeutics Inc. compare | −11.3% |
| XNCR Xencor, Inc. compare | −29.1% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −30.0% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| MBX MBX Biosciences, Inc. compare | −33.2% |
| IDYA IDEAYA Biosciences, Inc. compare | −38.5% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| PHVS Pharvaris N.V. compare | −71.5% |
| RCUS Arcus Biosciences, Inc. | −114.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement